Replies to post #240325 on Avid Bioservices Inc (CDMO)

[BioBS2012]

A topline analysis revealed that treatment with KEYTRUDA was associated with longer overall survival (OS) compared with docetaxel treatment

Probably will be presented at a conference later would be my guess. Right now it is all about trying to keep up with Nivolumab.

As to actual #'s I doubt they are very different then what is known regarding Nivolumab and Docetaxel, or else they would have been screaming that from the rooftops.

Cheers.